CA-DENODO
11.3.2020 08:02:06 CET | Business Wire | Press release
Denodo , the leader in data virtualization, today announced that it has been recognized in the Gartner Peer Insights “Voice of the Customer”: Data Integration Tools, 4 December, 2019 as the only data integration product that was recommended by 100 percent of the reviewers. With an overall rating of 4.5 out of 5, Denodo received the second highest ranking of the fifteen eligible vendors for Evaluation and Contracting. It also rated 4.5 out of 5 for Product Capabilities and Integration and Deployment respectively and 4.4 out of 5 for Service and Support*. The complete list of Gartner Peer Insights user reviews and ratings published within the twelve months ending 31st October 2019, can be seen here .
According to Gartner, “The market for data integration tools includes vendors that offer software products to enable the construction and implementation of data access and data delivery infrastructure for a variety of data integration scenarios. For vendors, the demand for traditional data integration capabilities alongside the demand for innovative solutions requires robust, consistent delivery of highly developed solutions. Similarly, data integration tools interoperate and integrate with master data tools, data governance tools and data quality tools.”
Sample and actual reviews from customers include:
- “The technology from Denodo is mature, stable and solid, with new desirable features being added quarterly. The pricing model is totally easy and logical (priced per production CPU cores, no other fees other than their optional but superb professional services).” The full review can be seen here .
- “Data abstraction, federation, and caching capabilities have worked extremely well. The quality of interactions with the Denodo staff from Sales to Support have been top-notch. The ability to influence the product roadmap has provided a path to help ensure that desired features/capabilities are implemented.” The full review can be seen here .
Denodo was also recognized for the second year as a Challenger in the 2019 Gartner Magic Quadrant for Data Integration Tools placing furthest in completeness of vision in the Challengers quadrant this year. This report recognizes that the market for data integration tools “continues to evolve and is supported by strong levels of adoption.”
“We are absolutely thrilled to receive such high ratings from by our customers as we believe it speaks to the fact that our end customers are extremely satisfied with our product, services and support,” said Ravi Shankar, SVP and CMO, Denodo. “We are constantly striving to ensure our data virtualization platform delivers tremendous value and sincerely thank our customers for their continued confidence and support.”
*Overall Rating and Willingness to Recommend are based on 35 total reviews within one-year period ending October 31, 2019; Product Capabilities is based on 35 reviews; Evaluation and Contracting is based on 27 reviews; Integration and Deployment is based on 33 reviews; and Service & Support is based on 35 reviews.
Sources: Gartner, Gartner Peer Insights ‘Voice of the Customer’: Data Integration Tools, Peer Contributors, 4 December 2019. Gartner, Magic Quadrant for Data Integration Tools, Ehtisham Zaidi, Eric Thoo, Nick Heudecker, 1 August 2019.
About Peer Insights
Peer Insights is an online platform of ratings and reviews of IT software and services that are written and read by IT professionals and technology decision-makers. The goal is to help IT leaders make more insightful purchase decisions and help technology providers improve their products by receiving objective, unbiased feedback from their customers. Gartner Peer Insights includes more than 70,000 verified reviews in more than 200 markets. For more information, please visit www.gartner.com .
Required Disclaimers
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights reviews constitute the subjective opinions of individual end users based on their own experiences and do not represent the views of Gartner or its affiliates.
Please Tweet: #datavirtualization expert @denodo Receives 100% ‘Willingness to Recommend’ by Reviewers in 2020 @Gartner_inc “Voice of the Customer”: Data Integration Tools. (https://buff.ly/38DBaxg )
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200311005022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom